

Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Liwei Ni, Jiyuan Ding, Junyan kou, Tingting Shao, Jun Li, Liujie Gao, Wanzhen Zheng, Jing huang*, Zhen Wu*


Department of Oncology, Hangzhou cancer hospital, Hangzhou, Zhejiang, 310000, P.R. China



sFig.1 Meta-analysis of the association between PNI and overall survival stratified by cutoff value among patients treated with immune checkpoint inhibitors




sFig.2 Meta-analysis of the association between PNI and overall survival stratified by analysis method among patients treated with immune checkpoint inhibitors




sFig.3 Meta-analysis of the association between PNI and overall survival stratified by country among patients treated with immune checkpoint inhibitors

Study ID	HR (95% CI)	% Weight
Gastrointestinal cancer		
Watanabe(2021)	2.40 (1.38, 4.15)	11.74
Kim(2021)	5.02 (1.21, 20.76)	4.53
Namikawa(2020)	1.39 (0.58, 3.34)	8.21
Subtotal (I-squared = 17.5%, p = 0.298)	2.24 (1.33, 3.78)	24.47
ung cancer		
.iu(2021) —	7.22 (4.08, 12.78)	11.48
Qi(2021)	1.13 (0.38, 3.36)	6.45
Dgura(2021)	- 1.80 (0.54, 5.98)	5.70
Zaitsu(2021)	0.98 (0.31, 3.13)	5.98
Peng(2020)	2.79 (1.57, 4.95)	11.45
Matsubara(2020)	■ 7.28 (0.92, 57.40)	2.51
Shoji(2019)	1.61 (0.95, 2.75)	11.98
Subtotal (I-squared = 72.5%, p = 0.001)	2.36 (1.28, 4.35)	55.53
Other type		
Shimizu(2020)	2.15 (0.57, 8.11)	4.99
Johannet(2020)	1.65 (1.27, 2.13)	15.01
Subtotal (I-squared = 0.0%, p = 0.701)	1.67 (1.29, 2.15)	19.99
Overall (I-squared = 63.5%, p = 0.002)	2.24 (1.57, 3.20)	100.00
NOTE: Weights are from random effects analysis		


sFig.4 Meta-analysis of the association between PNI and overall survival stratified by cancer type among patients treated with immune checkpoint inhibitors




sFig.5 Meta-analysis of the association between PNI and progressive-free survival stratified by cutoff value among patients treated with immune checkpoint inhibitors




sFig.6 Meta-analysis of the association between PNI and progressive-free survival stratified by cancer type among patients treated with immune checkpoint inhibitors




sFig.7 Meta-analysis of the association between PNI and progressive-free survival stratified by analysis method among patients treated with immune checkpoint inhibitors




sFig.8 Meta-analysis of the association between PNI and progressive-free survival stratified by country among patients treated with immune checkpoint inhibitors




sFig.9 Metatrim test of studies included in meta-analysis of PNI for OS (new pHR = 2.169, 95%CI = 1.524-3.086)



sFig.10 Metaninf test of studies included in meta-analysis of PNI for OS



sFig.11 Metatrim test of studies included in meta-analysis of PNI for PFS (new pHR = 1.580, 95%CI = 1.580–1.353)



sFig.12 Metaninf test of studies included in meta-analysis of PNI for PFS